explore -WSS

explore

author：focus 2025-10-01 17:21:09 - browse：47

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Chemotherapy shortages won’t get better under Biden’s latest plan

Wikipedia

WSS

Eli Lilly reports tirzepatide MASH success during Q4 earnings

STAT Boddities: What happens to the brain when we get scared?

Pregnancy discrimination could be enabled by AI

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Pfizer plans to depart BIO

What PEPFAR has meant on the ground in Ukraine

focus

explore

explore

Heart attack and stroke risk calculators need revising

Study gives hint on South Asians’ higher risk of cardiovascular disease

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Leukemia patients are helped by Syndax's new type of therapy

Supreme Court strikes down use of affirmative action

Spinal cord stimulation reduces pain in amputees, study finds

In Memoriam: Notable people who died in 2023

Doctors on social media are being harassed and cyberbullied

Continuity nursing helped my family in our darkest PICU moments

Abbott's new heart device gets FDA advisory panel nod

focus

Long Covid research funding gets a major boost from NIH

After sickle

Pharma patents targeted by Biden in move to slash drug prices

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Patients' immediate access to test results puts radiologists in a bind

focus

Wikipedia

hotspot

leisure time